⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374930 | 1.00 | — | — | |
| SCHEMBL24478321 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL21774704 | 0.98 | SLC6A1 (0.96) | — | |
| Hydrochloric Acid SCHEMBL21774701 | 0.98 | SLC6A1 (0.96) | — | |
| Hydrochloric Acid SCHEMBL22655757 | 0.98 | SLC6A1 (0.96) | — | |
| Acetic Acid SCHEMBL8859076 | 0.94 | SLC6A1 (0.88) | — | |
| Trifluoroacetic Acid SCHEMBL28718426 | 0.89 | SLC6A1 (0.79) | — | |
| SCHEMBL1225755 | 0.87 | SLC6A1 (0.77) | — | |
| SCHEMBL18828784 | 0.87 | SLC6A1 (0.77) | — | |
| SCHEMBL18828823 | 0.87 | SLC6A1 (0.77) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220213090-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | disclosed |
| EP-3558963-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| US-20170349586-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9714246-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714246-B2 | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9662339-B2 | Benzodioxane inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-2822941-B1 | BENZODIOXANES IN COMBINATION WITH STATINS FOR INHIBITING LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289226-A1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| EP-2547672-A1 | SUBSTITUTED PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20130005728-A1 | SUBSTITUTED PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2011115940-A1 | SUBSTITUTED PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | WO | disclosed |